



Closing the Precision Oncology Gap

We create clarity for patients and their clinicians by removing barriers to precision oncology testing in order to make timely, personalized cancer treatments a reality for all.

Decentralizing Comprehensive Genomic Profiling (CGP)

All patients deserve to have access to best-in-class genomic testing. PGDx is dedicated to empowering personalized care for all patients by bringing precision oncology testing to where they are.



Democratizing access to CGP with distributed kits



Delivering rapid insights to guide personalized treatment decisions



Elevating the standard of cancer care for all

Actionable Insights | Personalized Care

PGDx elio™ tissue complete

The PGDx elio™ tissue complete test enables rapid and actionable genomic insights for all patients with advanced cancer. Our FDA cleared and CE-IVD marked comprehensive tumor profiling kit is available for pathology labs to help every patient receive the personalized treatment options they deserve.




PGDx elio tissue complete:
a tumor tissue CGP IVD test

- ✓ FDA cleared, CE-IVD marked
- ✓ 500+ solid tumor-related genes
- ✓ Highly accurate somatic mutation identification including SNVs, indels, TMB, MSI, and select amplifications (1) and translocations (4)

For in vitro diagnostic use.

Streamline your NGS Workflow

From extracted DNA to automatically generated clinical reports, PGDx has developed methods to optimize your NGS workflow and results. Streamline your lab with our proven technology that delivers high-quality comprehensive genomic profiling (CGP) insights.





Comprehensive Biomarker Analysis and Discovery for Cancer Research

Accelerate novel discoveries in your precision oncology research programs with our highly sensitive and accurate assays that are backed by advanced proprietary bioinformatics.



PGDx elio tissue complete:

a tumor tissue CGP assay

- ✓ Customizable reporting
- ✓ 500+ solid tumor-related genes
- ✓ Somatic mutation identification: SNVs, indels, TMB, MSI, select amplifications (28) and translocations (20)

PGDx elio plasma complete:

a liquid biopsy CGP assay

- ✓ >95% concordance with comparator methods
- ✓ 500+ solid tumor-related genes
- ✓ Somatic mutation identification: SNVs, indels, bTMB, MSI, LOH, select amplifications and translocations

PGDx elio plasma resolve:

a focused liquid biopsy assay

- ✓ FDA breakthrough device designation on MSI
- ✓ 33 full coding genes for clinically relevant genes based on professional guidelines
- ✓ Somatic mutation identification: SNVs, indels, MSI, select amplifications & translocations

For Research Use Only. Not for use in diagnostic procedures.



In-House: our distributed model facilitates in-house precision oncology



Full Control: maintain control of samples and a rich feed of molecular data



Rapid: sample-to-result turnaround time as little as 4-5 days

Unlock a Deeper Understanding of Tumor Biology

PGDx elio bioinformatics rapidly and accurately identifies cancer mutations, empowering every lab with timely and trustworthy results. High quality training data, expert curation and machine learning algorithms combine to provide best-in-class identification of cancer mutations.

- **Automated:** turn-key workflow simplifies adoption and scaling
- **Accurate:** 100x more high-quality training data than other pipelines
- **Unparalleled:** proven artificial intelligence-based approach

Learn more about PGDx at PersonalGenome.com

For more details about our products, contact Sales@PGDx.com

Personal Genome Diagnostics Inc. | 3600 Boston Street, Suite 10 | Baltimore, Maryland 21224 | (855) 743-9669
 ©2022 Personal Genome Diagnostics Inc. All Rights Reserved. | MKPR-014-050622 - For Global Marketing Use.

Personal Genome Diagnostics offers RUO and IVD products. Refer to product documentation for complete intended use statements. Personal Genome Diagnostics Inc. (PGDx) is a subsidiary of Laboratory Corporation of America Holdings, using the brand Labcorp.

